Scorpius Holdings (SCPX) Stock News

Welcome to our dedicated page for Scorpius Holdings news (Ticker: SCPX), a resource for investors and traders seeking the latest updates and insights on Scorpius Holdings stock.

Scorpius Holdings, Inc. (SCPX) is a biotechnology-focused contract development and manufacturing organization (CDMO) that regularly issues news on its biologics and cell therapy manufacturing activities, strategic initiatives, and capital markets developments. Its updates provide insight into how the company supports pharmaceutical and biotech clients through analytical testing, process development, and cGMP manufacturing at its facilities in San Antonio, Texas.

News releases frequently highlight client collaborations and manufacturing agreements. Examples include Scorpius BioManufacturing’s GMP manufacturing validation agreement with Tivic Health Systems, Inc. for Entolimod™, a TLR5 agonist for Acute Radiation Syndrome, and a collaboration with KaloCyte to enhance manufacturing efficiencies for ErythroMer™, a dried, bio-inspired artificial red blood cell. These announcements illustrate Scorpius’ role in advancing innovative therapeutic programs toward the clinic and potential commercialization.

Investors and industry observers can also follow corporate strategy and restructuring updates, such as cost optimization initiatives, workforce reductions, and consolidation of operations into a single location intended to streamline the business and improve capital efficiency. The company has reported membership in the Medical CBRN Defense Consortium and the launch of Scorpius Ventures, a hybrid fee-and-equity unit designed to support emerging biotech companies and onshore U.S. biomanufacturing in alignment with BIOSECURE Act goals.

Scorpius’ news flow further covers capital markets and listing matters, including announcements about a planned and then cancelled reverse stock split, as well as notices from NYSE American regarding delisting proceedings and filing compliance. By reviewing the SCPX news page, readers can track developments in client partnerships, operational realignment, financing activities, and strategic alternatives that shape the company’s trajectory in the CDMO and biotechnology landscape.